skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1]
  1. Department of Radiation Oncology, Swedish Cancer Institute, Seattle, WA (United States)

Although radiotherapy improves locoregional control and survival in patients with non-small-cell lung cancer, radiation pneumonitis is a common treatment-related toxicity. Many pulmonary function tests are not significantly altered by pulmonary toxicity of irradiation, but reductions in DL{sub CO}, the diffusing capacity of carbon monoxide, are more commonly associated with pneumonitis. Several patient-specific factors (e.g. age, smoking history, tumor location, performance score, gender) and treatment-specific factors (e.g. chemotherapy regimen and dose) have been proposed as potential predictors of the risk of radiation pneumonitis, but these have not been consistently demonstrated across different studies. The risk of radiation pneumonitis also seems to increase as the cumulative dose of radiation to normal lung tissue increases, as measured by dose-volume histograms. However, controversy persists about which dosimetric parameter optimally predicts the risk of radiation pneumonitis, and whether the volume of lung or the dose of radiation is more important. Radiation oncologists ought to consider these dosimetric factors when designing radiation treatment plans for all patients who receive thoracic radiotherapy. Newer radiotherapy techniques and technologies may reduce the exposure of normal lung to irradiation. Several medications have also been evaluated for their ability to reduce radiation pneumonitis in animals and humans, including corticosteroids, amifostine, ACE inhibitors or angiotensin II type 1 receptor blockers, pentoxifylline, melatonin, carvedilol, and manganese superoxide dismutase-plasmid/liposome. Additional research is warranted to determine the efficacy of these medications and identify nonpharmacologic strategies to predict and prevent radiation pneumonitis.

OSTI ID:
20698520
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 63, Issue 1; Other Information: DOI: 10.1016/j.ijrobp.2005.03.047; PII: S0360-3016(05)00582-1; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English

Similar Records

Radiation Pneumonitis: Correlation of Toxicity With Pulmonary Metabolic Radiation Response
Journal Article · Tue Jul 15 00:00:00 EDT 2008 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698520

Updated assessment of the six-minute walk test as predictor of acute radiation-induced pneumonitis
Journal Article · Thu Mar 01 00:00:00 EST 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698520

Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis
Journal Article · Sat Jul 15 00:00:00 EDT 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20698520